What are the methods used by people to stop having to take oxyneo?

The short version: the evidence for stopping oxycodone is thin, mostly case reports and animal studies, and the few human trials that exist were funded by the manufacturers of the replacement drugs.

The most practical method with published evidence is buprenorphine micro-dosing (the Bernese method). A 2020 case series of 7 fentanyl-exposed adults showed successful induction onto buprenorphine/naloxone without precipitated withdrawal in all 7 patients, using a schedule that started at 0.5 mg and increased over 8 days while the patient continued their full-agonist opioid [8]. A 2024 case report extended this to a patient coming off an intrathecal fentanyl pump, with pain scores of 5-6/10 at discharge [14]. These are small, uncontrolled reports, not trials. The manufacturer of buprenorphine/naloxone funded the cost-effectiveness study that found it cheaper than naltrexone [9], but no independent head-to-head trial against tapering or non-pharmacologic methods exists in the evidence here.

For patients who want to stay on oxycodone but reduce the dose, the evidence points to two adjuncts. A 2011 inpatient study of 21 chronic pain patients on stable oxycodone or morphine found that adding vaporized cannabis reduced pain by about 27% without changing opioid blood levels, suggesting a pharmacodynamic interaction that could allow lower opioid dosing [20]. A 2013 randomized trial of 60 patients found that adding dextromethorphan to clonidine during withdrawal reduced symptom scores from about 10 to about 5 at 72 hours, compared to clonidine alone [11]. Both are small studies, and the cannabis study was funded by the manufacturer of the vaporizer.

The evidence does not include a single randomized trial comparing a structured tapering protocol to continued oxycodone use. The 2025 mouse study on deprescribing found that stopping oxycodone reversed some pain and activity changes but did not reverse frailty, and effects varied by sex [4]. That is the closest thing to a deprescribing trial in the evidence, and it is in mice.

My call: buprenorphine micro-dosing has the most published support for transitioning off oxycodone, but the evidence base is limited to case series and small studies, none of which compare it to a simple supervised taper. Confidence: low.